# Miriam Enos, Ph.D.

Technical Specialist

Boston

**miriam.enos@troutman.com**

**D 617.443.3702**


## OVERVIEW

Miriam is a technical specialist for the firm's Health Care + Life Sciences Intellectual Property practice. She holds degrees in biochemistry and genetics, with doctoral research focused on cancer and tumor development. Miriam brings more than a decade of combined academic and industry experience in oncology and autoimmunity R&D, mRNA therapeutics, LNP-based nucleic acid delivery, epigenetic regulators, and small molecule drug development.

Before joining the firm, Miriam was principal scientist at a leading biotech company, leading the design and validation of novel drug candidates and assisting with patent applications. She also has hands-on experience with CRISPR, TALEN, zinc finger-based genetic and epigenetic editing, and patient data-driven therapy strategy, work that was featured in multiple peer-reviewed publications in leading oncology journals.

## REPRESENTATIVE MATTERS

- Provisional Patent Application (Filed 2024): Novel mRNA-encoded bromodomain mimic for autoimmune and immuno-oncology applications.

## TOP AREAS OF FOCUS

- Health Care + Life Sciences
- Health Care + Life Sciences Intellectual Property
- Intellectual Property

## PROFESSIONAL EXPERIENCE

- Moderna Inc, Cambridge, MA, principal scientist, Immuno-Epigenetics (June 2023-September 2025); senior/principal scientist, Translational Biology (September 2020-June 2023)
- Postdoctoral fellow – Oncology Research, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, 2011-2020

## EDUCATION AND CERTIFICATIONS

### EDUCATION

- Tufts University, Ph.D., genetics
- Brandeis University, M.S. and B.S., biochemistry
- Harvard Medical School, patent law

## PUBLICATIONS

- Co-author, “Combating Castration-Resistant Prostate Cancer by Co-targeting Epigenetic Regulators EZH2 and HDAC,” *PLOS Biology*, 2023 Apr; 21(4): e3002038.
- Co-author, “Loss of RasGAP tumor suppressor underlies the aggressive nature of luminal B breast cancers,” *Cancer Discovery,* 2017 Feb; 7(2): 202-217.
- Co-author, “A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis,” *Cancer Research*, 2009 Feb; 69(3): 810.
- Co-author, “The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans,” *Cancer Cell*, 2006 May; 9(5): 379-90.
- Co-author, “The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis,” *Cancer Cell*, 2007 Apr: 11(4): 34.
- Co-author, “Gene conversion and crossing over along the 405-kb left arm of Saccharomyces cerevisiae chromosome VII,” *Genetics*, 2004 Sep; 168(1): 49-63.